These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35813250)

  • 41. Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies.
    Kikuchi E; Hayakawa N; Fukumoto K; Shigeta K; Matsumoto K
    Int J Urol; 2020 Feb; 27(2):108-116. PubMed ID: 31793703
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
    Kim HS; Seo HK
    Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
    Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
    Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
    Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Matsumura Y; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
    Int J Urol; 2022 Mar; 29(3):242-249. PubMed ID: 34902876
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.
    Lucca I; Derré L; Cesson V; Bohner P; Crettenand F; Rodrigues-Dias S; Dartiguenave F; Masnada A; Texeira-Pereira C; Benmerzoug S; Chevalier M; Domingos-Pereira S; Nguyen S; Polak L; Schneider A; Roth B; Jichlinski P; Nardelli-Haefliger D
    Eur Urol Open Sci; 2022 Nov; 45():55-58. PubMed ID: 36212980
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
    Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
    Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Use of Urine
    Muto S; Lu Y; Ide H; Yamaguchi R; Saito K; Kitamura K; Noma Y; Koyasu H; Hirano H; Ashizawa T; Isotani S; Nagata M; Horie S
    Eur Urol Open Sci; 2021 May; 27():10-18. PubMed ID: 34337512
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
    Gandhi NM; Morales A; Lamm DL
    BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group.
    Nseyo UO; Shumaker B; Klein EA; Sutherland K
    J Urol; 1998 Jul; 160(1):39-44. PubMed ID: 9628601
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
    Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
    Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.
    Lobo N; Hensley PJ; Bree KK; Nogueras-Gonzalez GM; Navai N; Dinney CP; Sylvester RJ; Kamat AM
    Eur Urol Oncol; 2022 Feb; 5(1):84-91. PubMed ID: 34920986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
    Meng MV; Gschwend JE; Shore N; Grossfeld GD; Mostafid H; Black PC
    J Urol; 2019 Dec; 202(6):1111-1119. PubMed ID: 31042108
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
    Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
    BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients.
    de Jong JJ; Hendricksen K; Rosier M; Mostafid H; Boormans JL
    Bladder Cancer; 2018 Oct; 4(4):395-401. PubMed ID: 30417050
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design.
    Matulay JT; Li R; Hensley PJ; Brooks NA; Narayan VM; Grossman HB; Navai N; Dinney CPN; Kamat AM
    J Urol; 2021 Jun; 205(6):1612-1621. PubMed ID: 33502236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
    Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?
    Sari Motlagh R; Pradere B; Mori K; Miura N; Abufaraj M; Shariat SF
    Curr Opin Urol; 2020 Jul; 30(4):584-593. PubMed ID: 32304379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
    Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
    Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.
    Nishiyama N; Kitamura H; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Masumori N
    Jpn J Clin Oncol; 2014 Nov; 44(11):1101-8. PubMed ID: 25139163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.